

# EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism



**Purpose:** A comparison of rivaroxaban to aspirin to determine whether rivaroxaban is better in to prevent the recurrence of symptomatic venous thromboembolism.

**Trial Design:** Phase 3, randomized, double-blinded; n= 3396. Rivaroxaban (either 10 mg daily or 20 mg daily for 12 months) vs. aspirin 100 mg daily for 12 months.

**Primary Endpoint:** % of patients with the recurrence of symptomatic venous thromboembolism (either DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)).

Trial Results	10 mg rivaroxaban	20 mg rivaroxaban	100 mg aspirin
% symptomatic VTE recurrence	1.2%	1.5%	4.4%
Major bleeding	0.4%	0.5%	0.3%

**Conclusions:** The risk for recurrent symptomatic VTE was lower with rivaroxaban than for aspirin in this group of patients. Bleeding rates were similar in all 3 groups.

